Literature DB >> 29315899

Expanded neurochemical profile in the early stage of Huntington disease using proton magnetic resonance spectroscopy.

Isaac M Adanyeguh1, Marie-Lorraine Monin1,2, Daisy Rinaldi1, Léorah Freeman3, Alexandra Durr1,2, Stéphane Lehéricy1,4, Pierre-Gilles Henry5, Fanny Mochel1,2,6.   

Abstract

The striatum is a well-known region affected in Huntington disease (HD). However, other regions, including the visual cortex, are implicated. We have identified previously an abnormal energy response in the visual cortex of patients at an early stage of HD using 31 P magnetic resonance spectroscopy (31 P MRS). We therefore sought to further characterize these metabolic alterations with 1 H MRS using a well-validated semi-localized by adiabatic selective refocusing (semi-LASER) sequence that allows the measurement of an expanded number of neurometabolites. Ten early affected patients [Unified Huntington Disease Rating Scale (UHDRS), total motor score = 13.6 ± 10.8] and 10 healthy volunteers of similar age and body mass index (BMI) were recruited for the study. We performed 1 H MRS in the striatum - the region that is primarily affected in HD - and the visual cortex. The protocol allowed a reliable quantification of 10 metabolites in the visual cortex and eight in the striatum, compared with three to five metabolites in previous 1 H MRS studies performed in HD. We identified higher total creatine (p < 0.05) in the visual cortex and lower glutamate (p < 0.001) and total creatine (p < 0.05) in the striatum of patients with HD compared with controls. Less abundant neurometabolites [glutamine, γ-aminobutyric acid (GABA), glutathione, aspartate] showed similar concentrations in both groups. The protocol allowed the measurement of several additional metabolites compared with standard vendor protocols. Our study points to early changes in metabolites involved in energy metabolism in the visual cortex and striatum of patients with HD. Decreased striatal glutamate could reflect early neuronal dysfunction or impaired glutamatergic neurotransmission.
Copyright © 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  1H MRS; Huntington disease; movement disorders; neurochemical profile; neurometabolite; semi-LASER

Mesh:

Year:  2018        PMID: 29315899      PMCID: PMC5841244          DOI: 10.1002/nbm.3880

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  44 in total

Review 1.  Energy defects in Huntington's disease: Why "in vivo" evidence matters.

Authors:  Géraldine Liot; Julien Valette; Jérémy Pépin; Julien Flament; Emmanuel Brouillet
Journal:  Biochem Biophys Res Commun       Date:  2016-09-14       Impact factor: 3.575

2.  7-T (1) H MRS with adiabatic refocusing at short TE using radiofrequency focusing with a dual-channel volume transmit coil.

Authors:  V O Boer; A L H M W van Lier; J M Hoogduin; J P Wijnen; P R Luijten; D W J Klomp
Journal:  NMR Biomed       Date:  2011-02-04       Impact factor: 4.044

3.  Triheptanoin improves brain energy metabolism in patients with Huntington disease.

Authors:  Isaac Mawusi Adanyeguh; Daisy Rinaldi; Pierre-Gilles Henry; Samantha Caillet; Romain Valabregue; Alexandra Durr; Fanny Mochel
Journal:  Neurology       Date:  2015-01-07       Impact factor: 9.910

4.  Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo 1H NMR spectroscopy.

Authors:  Ivan Tkac; Janet M Dubinsky; C Dirk Keene; Rolf Gruetter; Walter C Low
Journal:  J Neurochem       Date:  2007-01-08       Impact factor: 5.372

5.  Protective effect of the energy precursor creatine against toxicity of glutamate and beta-amyloid in rat hippocampal neurons.

Authors:  G J Brewer; T W Wallimann
Journal:  J Neurochem       Date:  2000-05       Impact factor: 5.372

6.  1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers.

Authors:  B G Jenkins; H D Rosas; Y C Chen; T Makabe; R Myers; M MacDonald; B R Rosen; M F Beal; W J Koroshetz
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

7.  Huntington's Disease (HD): Neurodegeneration of Brodmann's Primary Visual Area 17 (BA17).

Authors:  Udo Rüb; Kay Seidel; Jean Paul Vonsattel; Herwig W Lange; Wolfgang Eisenmenger; Monika Götz; Domenico Del Turco; Mohamed Bouzrou; Horst-Werner Korf; Helmut Heinsen
Journal:  Brain Pathol       Date:  2015-01-27       Impact factor: 6.508

8.  1H magnetic resonance spectroscopy in preclinical Huntington disease.

Authors:  Joost C H van Oostrom; Paul E Sijens; Raymund A C Roos; Klaus L Leenders
Journal:  Brain Res       Date:  2007-07-17       Impact factor: 3.252

9.  Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.

Authors:  Sarah J Tabrizi; Rachael I Scahill; Gail Owen; Alexandra Durr; Blair R Leavitt; Raymund A Roos; Beth Borowsky; Bernhard Landwehrmeyer; Chris Frost; Hans Johnson; David Craufurd; Ralf Reilmann; Julie C Stout; Douglas R Langbehn
Journal:  Lancet Neurol       Date:  2013-05-09       Impact factor: 44.182

10.  Exploratory 7-Tesla magnetic resonance spectroscopy in Huntington's disease provides in vivo evidence for impaired energy metabolism.

Authors:  Simon J A van den Bogaard; Eve M Dumas; Wouter M Teeuwisse; Hermien E Kan; Andrew Webb; Raymund A C Roos; Jeroen van der Grond
Journal:  J Neurol       Date:  2011-05-26       Impact factor: 4.849

View more
  1 in total

1.  Reproducibility of brain MRS in older healthy adults at 7T.

Authors:  S Andrea Wijtenburg; Laura M Rowland; Georg Oeltzschner; Peter B Barker; Clifford I Workman; Gwenn S Smith
Journal:  NMR Biomed       Date:  2018-11-29       Impact factor: 4.044

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.